Search for "six-membered ring" in Full Text gives 144 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2023, 19, 892–900, doi:10.3762/bjoc.19.67
Graphical Abstract
Scheme 1: Versatile reactivities of cyclopropanes 1a.
Scheme 2: Preparative methods for cyclopropanedicarboxylates 1a.
Scheme 3: Bromination of ethyl acetoacetate (3c) and reaction with nitrostyrene 2a.
Scheme 4: Reaction of 4b with (diacetoxyiodo)benzene (top); structural determination of product 9 (bottom).
Figure 1: Monitoring the cyclization reaction using 4e by 1H NMR.
Scheme 5: A plausible mechanism for formation of cyclopropane 1 and dihydrofuran 8.
Scheme 6: Tin(II)-mediated ring expansion of nitrocyclopropane 1e.
Beilstein J. Org. Chem. 2023, 19, 658–665, doi:10.3762/bjoc.19.47
Graphical Abstract
Figure 1: Chemical structures of 1-3 isolated from P. macropterum.
Figure 2: Key 1H,1H-COSY, and HMBC correlations of 1 and 3.
Figure 3: Selected NOESY cross peaks of 1 and 3.
Figure 4: Measured and predicted ECD spectra of 1 and 3.
Beilstein J. Org. Chem. 2023, 19, 245–281, doi:10.3762/bjoc.19.23
Graphical Abstract
Figure 1: Examples of terpenes containing a bicyclo[3.6.0]undecane motif.
Figure 2: Commercially available first and second generation Grubbs and Hoveyda–Grubbs catalysts.
Figure 3: Examples of strategies to access the fusicoccan and ophiobolin tricyclic core structure by RCM.
Scheme 1: Synthesis of bicyclic core structure 12 of ophiobolin M (13) and cycloaraneosene (14).
Scheme 2: Synthesis of the core structure 21 of ophiobolins and fusicoccanes.
Scheme 3: Ring-closing metathesis attempts starting from thioester 22.
Scheme 4: Total synthesis of ent-fusicoauritone (28).
Figure 4: General structure of ophiobolins and congeners.
Scheme 5: Total synthesis of (+)-ophiobolin A (8).
Scheme 6: Investigation of RCM for the synthesis of ophiobolin A (8). Path A) RCM with TBDPS-protected alcoho...
Scheme 7: Synthesis of the core structure of cotylenin A aglycon, cotylenol (50).
Scheme 8: Synthesis of tricyclic core structure of fusicoccans.
Scheme 9: Total synthesis of (−)-teubrevin G (59).
Scheme 10: Synthesis of the core skeleton 63 of the basmane family.
Scheme 11: Total synthesis of (±)-schindilactone A (68).
Scheme 12: Total synthesis of dactylol (72).
Scheme 13: Ring-closing metathesis for the total synthesis of (±)-asteriscanolide (2).
Scheme 14: Synthesis of the simplified skeleton of pleuromutilin (1).
Scheme 15: Total synthesis of (−)-nitidasin (93) using a ring-closing metathesis to construct the eight-member...
Scheme 16: Total synthesis of (±)-naupliolide (97).
Scheme 17: Synthesis of the A-B ring structure of fusicoccane (101).
Scheme 18: First attempts of TRCM of dienyne substrates.
Scheme 19: TRCM on optimized substrates towards the synthesis of ophiobolin A (8).
Scheme 20: Tandem ring-closing metathesis for the synthesis of variecolin intermediates 114 and 115.
Scheme 21: Synthesis of poitediol (118) using the allylsilane ring-closing metathesis.
Scheme 22: Access to scaffold 122 by a NHK coupling reaction.
Scheme 23: Key step to construct the [5-8] bicyclooctanone core of aquatolide (4).
Scheme 24: Initial strategy to access aquatolide (4).
Scheme 25: Synthetic plan to cotylenin A (130).
Scheme 26: [5-8] Bicyclic structure of brachialactone (7) constructed by a Mizoroki–Heck reaction.
Scheme 27: Influence of the replacement of the allylic alcohol moiety.
Scheme 28: Formation of variecolin intermediate 140 through a SmI2-mediated Barbier-type reaction.
Scheme 29: SmI2-mediated ketyl addition. Pleuromutilin (1) eight-membered ring closure via C5–C14 bond formati...
Scheme 30: SmI2-mediated dialdehyde cyclization cascade of [5-8-6] pleuromutilin scaffold 149.
Scheme 31: A) Modular synthetic route to mutilin and pleuromutilin family members by Herzon’s group. B) Scaffo...
Scheme 32: Photocatalyzed oxidative ring expansion in pleuromutilin (1) total synthesis.
Scheme 33: Reductive radical cascade cyclization route towards (−)-6-epi-ophiobolin N (168).
Scheme 34: Reductive radical cascade cyclization route towards (+)-6-epi-ophiobolin A (173).
Scheme 35: Radical 8-endo-trig-cyclization of a xanthate precursor.
Figure 5: Structural representations of hypoestin A (177), albolic acid (178), and ceroplastol II (179) beari...
Scheme 36: Synthesis of the common [5-8-5] tricyclic intermediate of hypoestin A (177), albolic acid (178), an...
Scheme 37: Asymmetric synthesis of hypoestin A (177), albolic acid (178), and ceroplastol II (179).
Figure 6: Scope of the Pauson–Khand reaction.
Scheme 38: Nazarov cyclization revealing the fusicoauritone core structure 192.
Scheme 39: Synthesis of fusicoauritone (28) through Nazarov cyclization.
Scheme 40: (+)-Epoxydictymene (5) synthesis through a Nicholas cyclization followed by a Pauson–Khand reaction...
Scheme 41: Synthesis of aquatolide (4) by a Mukaiyama-type aldolisation.
Scheme 42: Tandem Wolff/Cope rearrangement furnishing the A-B bicyclic moiety 204 of variecolin.
Scheme 43: Asymmetric synthesis of the A-B bicyclic core 205 and 206 of variecolin.
Scheme 44: Formation of [5-8]-fused rings by cyclization under thermal activation.
Scheme 45: Construction of the [5-8-6] tricyclic core structure of variecolin (3) by Diels–Alder reaction.
Scheme 46: Synthesis of the [6-4-8-5]-tetracyclic skeleton by palladium-mediated cyclization.
Scheme 47: Access to the [5-8] bicyclic core structure of asteriscanolide (227) through rhodium-catalyzed cycl...
Scheme 48: Total syntheses of asterisca-3(15),6-diene (230) and asteriscanolide (2) with a Rh-catalyzed cycliz...
Scheme 49: Photocyclization of 2-pyridones to access the [5-8-5] backbone of fusicoccanes.
Scheme 50: Total synthesis of (+)-asteriscunolide D (245) and (+)-aquatolide (4) through photocyclization.
Scheme 51: Biocatalysis pathway to construct the [5-8-5] tricyclic scaffold of brassicicenes.
Scheme 52: Influence of the CotB2 mutant over the cyclization’s outcome of GGDP.
Beilstein J. Org. Chem. 2023, 19, 57–65, doi:10.3762/bjoc.19.5
Graphical Abstract
Figure 1: Representative natural products and biologically active molecules containing an oxindole moiety [7-13].
Scheme 1: Selected photocatalytic decarboxylative radical cascade reactions of N-arylamides.
Scheme 2: Arylamide substrate scope with isolated yields of products.
Scheme 3: Alkyl radical precursor scope with isolated yields of products.
Scheme 4: Selected mechanistic experiments.
Beilstein J. Org. Chem. 2022, 18, 1629–1635, doi:10.3762/bjoc.18.174
Graphical Abstract
Figure 1: Structures of halichonic acid ((+)-1) and halichonic acid B ((+)-2).
Scheme 1: Synthesis of (−)-7-amino-7,8-dihydrobisabolene (4) and its conversion to cyclization precursor 7.
Scheme 2: Synthesis of the halichonic acids via a key intramolecular aza-Prins cyclization.
Scheme 3: Proposed intermediates for the intramolecular aza-Prins reaction leading to the formation of ethyl ...
Beilstein J. Org. Chem. 2022, 18, 1424–1434, doi:10.3762/bjoc.18.148
Graphical Abstract
Figure 1: Adamantane-based tripodal scaffolds and current work.
Scheme 1: A general strategy for the assembly of TAAD derivatives.
Scheme 2: Synthesis of acyclic precursors to 3N-TAADs, 2N,1O-TAADs, and 1N,2O-TAADs.
Scheme 3: Synthesis of 3N-TAADs, 2N,1O-TAADs, and 1N,2O-TAADs. *Yield based on compound 14.
Scheme 4: Deprotection of TAAD 8b and subsequent complexation with phenylboronic acid.
Scheme 5: Quaternization of TAADs 4c, 4e, 6a, and 8a followed by deprotection of N-Boc groups.
Figure 2: General view of the 1,4,6,10-tetraazaadamantane motif in X-ray structures of the obtained N-TAAD de...
Figure 3: (a) General structure of host–guest complexes of 3N-TAADs with water. (b) The general structure of ...
Figure 4: (a) Dynamic processes in TAADs 4 and complexation with ROH. (b) Fragment of 1H NMR spectra of Bn-4c...
Beilstein J. Org. Chem. 2022, 18, 1100–1106, doi:10.3762/bjoc.18.112
Graphical Abstract
Figure 1: Plausible mechanism of the radical cation Diels–Alder reaction (EDG: electron-donating group).
Figure 2: Landscape of the radical cation Diels–Alder reaction.
Scheme 1: Radical cation Diels–Alder reaction of β-methylstyrene.
Scheme 2: Radical cation Diels–Alder reaction of β-methylanethole (1). Recovered starting material is reporte...
Figure 3: Formal expression of radical cations.
Scheme 3: Radical cation Diels–Alder reactions of the arylidene cycloalkanes (4–7). Recovered starting materi...
Scheme 4: Scope of the radical cation Diels–Alder reaction of arylidene cycloalkanes (recovered starting mate...
Beilstein J. Org. Chem. 2022, 18, 524–532, doi:10.3762/bjoc.18.54
Graphical Abstract
Figure 1: The structures of chloroquine, hydroxychloroquine, and amodiaquine.
Scheme 1: Synthesis of 3-azolylpyrazoles 3a–c.
Scheme 2: Assumed mechanism for the formation of 1H-pyrazoles 3a–c.
Scheme 3: Synthesis of 3-aminopyrazoles 5b–k and 5-aminopyrazoles 5a and 5l–o.
Scheme 4: Orientation of nucleophilic attack of 7-chloro-4-hydrazinylquinoline on nitrobutadienes 4.
Scheme 5: Synthesis of oxazolidine 6 and pyrazole 7.
Scheme 6: A plausible mechanism for the formation of pyrazole 7.
Scheme 7: Synthesis of pyrazoles 9 and sulfoxide 10d.
Scheme 8: Synthesis of pyrazole 11.
Beilstein J. Org. Chem. 2021, 17, 2348–2376, doi:10.3762/bjoc.17.153
Graphical Abstract
Scheme 1: Schematic representation of Hg(II)-mediated addition to an unsaturated bond.
Scheme 2: First report of Hg(II)-mediated synthesis of 2,5-dioxane derivatives from allyl alcohol.
Scheme 3: Stepwise synthesis of 2,6-distubstituted dioxane derivatives.
Scheme 4: Cyclization of carbohydrate alkene precursor.
Scheme 5: Hg(II)-mediated synthesis of C-glucopyranosyl derivatives.
Scheme 6: Synthesis of C-glycosyl amino acid derivative using Hg(TFA)2.
Scheme 7: Hg(OAc)2-mediated synthesis of α-ᴅ-ribose derivative.
Scheme 8: Synthesis of β-ᴅ-arabinose derivative 18.
Scheme 9: Hg(OAc)2-mediated synthesis of tetrahydrofuran derivatives.
Scheme 10: Synthesis of Hg(TFA)2-mediated bicyclic nucleoside derivative.
Scheme 11: Synthesis of pyrrolidine and piperidine derivatives.
Scheme 12: HgCl2-mediated synthesis of diastereomeric pyrrolidine derivatives.
Scheme 13: HgCl2-mediated cyclization of alkenyl α-aminophosphonates.
Scheme 14: Cyclization of 4-cycloocten-1-ol with Hg(OAc)2 forming fused bicyclic products.
Scheme 15: trans-Amino alcohol formation through Hg(II)-salt-mediated cyclization.
Scheme 16: Hg(OAc)2-mediated 2-aza- or 2-oxa-bicyclic ring formations.
Scheme 17: Hg(II)-salt-induced cyclic peroxide formation.
Scheme 18: Hg(OAc)2-mediated formation of 1,2,4-trioxanes.
Scheme 19: Endocyclic enol ether derivative formation through Hg(II) salts.
Scheme 20: Synthesis of optically active cyclic alanine derivatives.
Scheme 21: Hg(II)-salt-mediated formation of tetrahydropyrimidin-4(1H)-one derivatives.
Scheme 22: Cyclization of ether derivatives to form stereoselective oxazolidine derivatives.
Scheme 23: Cyclization of amide derivatives induced by Hg(OAc)2.
Scheme 24: Hg(OAc)2/Hg(TFA)2-promoted cyclization of salicylamide-derived amidal auxiliary derivatives.
Scheme 25: Hg(II)-salt-mediated cyclization to form dihydrobenzopyrans.
Scheme 26: HgCl2-induced cyclization of acetylenic silyl enol ether derivatives.
Scheme 27: Synthesis of exocyclic and endocyclic enol ether derivatives.
Scheme 28: Cyclization of trans-acetylenic alcohol by treatment with HgCl2.
Scheme 29: Synthesis of benzofuran derivatives in presence of HgCl2.
Scheme 30: a) Hg(II)-salt-mediated cyclization of 4-hydroxy-2-alkyn-1-ones to furan derivatives and b) its mec...
Scheme 31: Cyclization of arylacetylenes to synthesize carbocyclic and heterocyclic derivatives.
Scheme 32: Hg(II)-salt-promoted cyclization–rearrangement to form heterocyclic compounds.
Scheme 33: a) HgCl2-mediated cyclization reaction of tethered alkyne dithioacetals; and b) proposed mechanism.
Scheme 34: Cyclization of aryl allenic ethers on treatment with Hg(OTf)2.
Scheme 35: Hg(TFA)2-mediated cyclization of allene.
Scheme 36: Hg(II)-catalyzed intramolecular trans-etherification reaction of 2-hydroxy-1-(γ-methoxyallyl)tetrah...
Scheme 37: a) Cyclization of alkene derivatives by catalytic Hg(OTf)2 salts and b) mechanism of cyclization.
Scheme 38: a) Synthesis of 1,4-dihydroquinoline derivatives by Hg(OTf)2 and b) plausible mechanism of formatio...
Scheme 39: Synthesis of Hg(II)-salt-catalyzed heteroaromatic derivatives.
Scheme 40: Hg(II)-salt-catalyzed synthesis of dihydropyranone derivatives.
Scheme 41: Hg(II)-salt-catalyzed cyclization of alkynoic acids.
Scheme 42: Hg(II)-salt-mediated cyclization of alkyne carboxylic acids and alcohol to furan, pyran, and spiroc...
Scheme 43: Hg(II)-salt-mediated cyclization of 1,4-dihydroxy-5-alkyne derivatives.
Scheme 44: Six-membered morpholine derivative formation by catalytic Hg(II)-salt-induced cyclization.
Scheme 45: Hg(OTf)2-catalyzed hydroxylative carbocyclization of 1,6-enyne.
Scheme 46: a) Hg(OTf)2-catalyzed hydroxylative carbocyclization of 1,6-enyne. b) Proposed mechanism.
Scheme 47: a) Synthesis of carbocyclic derivatives using a catalytic amount of Hg(II) salt. b) Proposed mechan...
Scheme 48: Cyclization of 1-alkyn-5-ones to 2-methylfuran derivatives.
Scheme 49: Hg(NO3)2-catalyzed synthesis of 2-methylenepiperidine.
Scheme 50: a) Preparation of indole derivatives through cycloisomerization of 2-ethynylaniline and b) its mech...
Scheme 51: a) Hg(OTf)2-catalyzed synthesis of 3-indolinones and 3-coumaranones and b) simplified mechanism.
Scheme 52: a) Hg(OTf)2-catalyzed one pot cyclization of nitroalkyne and b) its plausible mechanism.
Scheme 53: Synthesis of tricyclic heterocyclic scaffolds.
Scheme 54: HgCl2-mediated cyclization of 2-alkynylphenyl alkyl sulfoxide.
Scheme 55: a) Hg(OTf)2-catalyzed cyclization of allenes and alkynes. b) Proposed mechanism of cyclization.
Scheme 56: Stereoselective synthesis of tetrahydropyran derivatives.
Scheme 57: a) Hg(ClO4)2-catalyzed cyclization of α-allenol derivatives. b) Simplified mechanism.
Scheme 58: Hg(TFA)2-promoted cyclization of a γ-hydroxy alkene derivative.
Scheme 59: Synthesis Hg(II)-salt-mediated cyclization of allyl alcohol for the construction of ventiloquinone ...
Scheme 60: Hg(OAc)2-mediated cyclization as a key step for the synthesis of hongconin.
Scheme 61: Examples of Hg(II)-salt-mediated cyclized ring formation in the syntheses of (±)-fastigilin C and (...
Scheme 62: Formal synthesis of (±)-thallusin.
Scheme 63: Total synthesis of hippuristanol and its analog.
Scheme 64: Total synthesis of solanoeclepin A.
Scheme 65: a) Synthesis of Hg(OTf)2-catalyzed azaspiro structure for the formation of natural products. b) Pro...
Beilstein J. Org. Chem. 2021, 17, 2194–2202, doi:10.3762/bjoc.17.141
Graphical Abstract
Figure 1: Structures of nomimicins A–D (4 and 1–3).
Figure 2: COSY and key HMBC correlations for 1.
Figure 3: Relative configuration of 1 determined by ROESY analysis.
Figure 4: Experimental ECD spectra of 1, 2, and 4 and calculated ECD spectrum of 4.
Figure 5: Four tautomers 4a–4d of the tetronic acid moiety of 4 and calculated ECD spectra.
Figure 6: COSY and key HMBC correlations for 3.
Figure 7: Relative configuration of 3 determined by NOESY analysis.
Beilstein J. Org. Chem. 2021, 17, 1565–1590, doi:10.3762/bjoc.17.112
Graphical Abstract
Figure 1: Some examples of natural products and drugs containing quaternary carbon centers.
Scheme 1: Simplified mechanism for olefin hydrofunctionalization using an electrophilic transition metal as a...
Scheme 2: Selected examples of quaternary carbon centers formed by the intramolecular hydroalkylation of β-di...
Scheme 3: Control experiments and the proposed mechanism for the Pd(II)-catalyzed intermolecular hydroalkylat...
Scheme 4: Intermolecular olefin hydroalkylation of less reactive ketones under Pd(II) catalysis using HCl as ...
Scheme 5: A) Selected examples of Pd(II)-mediated quaternary carbon center synthesis by intermolecular hydroa...
Scheme 6: Selected examples of quaternary carbon center synthesis by gold(III) catalysis. This is the first r...
Scheme 7: Selected examples of inter- (A) and intramolecular (B) olefin hydroalkylations promoted by a silver...
Scheme 8: A) Intermolecular hydroalkylation of N-alkenyl β-ketoamides under Au(I) catalysis in the synthesis ...
Scheme 9: Asymmetric pyrrolidine synthesis through intramolecular hydroalkylation of α-substituted N-alkenyl ...
Scheme 10: Proposed mechanism for the chiral gold(I) complex promotion of the intermolecular olefin hydroalkyl...
Scheme 11: Selected examples of carbon quaternary center synthesis by gold and evidence of catalytic system pa...
Scheme 12: Synthesis of a spiro compound via an aza-Michael addition/olefin hydroalkylation cascade promoted b...
Scheme 13: A selected example of quaternary carbon center synthesis using an Fe(III) salt as a catalyst for th...
Scheme 14: Intermolecular hydroalkylation catalyzed by a cationic iridium complex (Fuji (2019) [47]).
Scheme 15: Generic example of an olefin hydrofunctionalization via MHAT (Shenvi (2016) [51]).
Scheme 16: The first examples of olefin hydrofunctionalization run under neutral conditions (Mukaiyama (1989) [56]...
Scheme 17: A) Aryl olefin dimerization catalyzed by vitamin B12 and triggered by HAT. B) Control experiment to...
Scheme 18: Generic example of MHAT diolefin cycloisomerization and possible competitive pathways. Shenvi (2014...
Scheme 19: Selected examples of the MHAT-promoted cycloisomerization reaction of unactivated olefins leading t...
Scheme 20: Regioselective carbocyclizations promoted by an MHAT process (Norton (2008) [76]).
Scheme 21: Selected examples of quaternary carbon centers synthetized via intra- (A) and intermolecular (B) MH...
Scheme 22: A) Proposed mechanism for the Fe(III)/PhSiH3-promoted radical conjugate addition between olefins an...
Scheme 23: Examples of cascade reactions triggered by HAT for the construction of trans-decalin backbone uniti...
Scheme 24: A) Selected examples of the MHAT-promoted radical conjugate addition between olefins and p-quinone ...
Scheme 25: A) MHAT triggered radical conjugate addition/E1cB/lactonization (in some cases) cascade between ole...
Scheme 26: A) Spirocyclization promoted by Fe(III) hydroalkylation of unactivated olefins. B) Simplified mecha...
Scheme 27: A) Selected examples of the construction of a carbon quaternary center by the MHAT-triggered radica...
Scheme 28: Hydromethylation of unactivated olefins under iron-mediated MHAT (Baran (2015) [95]).
Scheme 29: The hydroalkylation of unactivated olefins via iron-mediated reductive coupling with hydrazones (Br...
Scheme 30: Selected examples of the Co(II)-catalyzed bicyclization of dialkenylarenes through the olefin hydro...
Scheme 31: Proposed mechanism for the bicyclization of dialkenylarenes triggered by a MHAT process (Vanderwal ...
Scheme 32: Enantioconvergent cross-coupling between olefins and tertiary halides (Fu (2018) [108]).
Scheme 33: Proposed mechanism for the Ni-catalyzed cross-coupling reaction between olefins and tertiary halide...
Scheme 34: Proposed catalytic cycles for a MHAT/Ni cross-coupling reaction between olefins and halides (Shenvi...
Scheme 35: Selected examples of the hydroalkylation of olefins by a dual catalytic Mn/Ni system (Shenvi (2019) ...
Scheme 36: A) Selected examples of quaternary carbon center synthesis by reductive atom transfer; TBC: 4-tert-...
Scheme 37: A) Selected examples of quaternary carbon centers synthetized by radical addition to unactivated ol...
Scheme 38: A) Selected examples of organophotocatalysis-mediated radical polyene cyclization via a PET process...
Scheme 39: A) Sc(OTf)3-mediated carbocyclization approach for the synthesis of vicinal quaternary carbon cente...
Scheme 40: Scope of the Lewis acid-catalyzed methallylation of electron-rich styrenes. Method A: B(C6F5)3 (5.0...
Scheme 41: The proposed mechanism for styrene methallylation (Oestreich (2019) [123]).
Beilstein J. Org. Chem. 2021, 17, 1509–1517, doi:10.3762/bjoc.17.108
Graphical Abstract
Figure 1: Structures of exemplary benzo- and heteroaromatic fused 1,4-quinone drugs and natural products.
Scheme 1: First [3 + 2]-cycloaddition of 1,4-naphthoquinone (1a) with intermediate nitrile imine 2, generated...
Scheme 2: Selected applications of trifluoroacetonitrile imines 7 in the synthesis of S-containing 5- and 6-m...
Scheme 3: Synthesis of [3 + 2]-cycloadducts 9a–l derived from CF3-substituted nitrile imines 7a–h and 1,4-qui...
Figure 2: X-ray structure of 3-trifluoromethylpyrazole derivative 9d. The labeling scheme of the asymmetric u...
Scheme 4: Thermal elimination of MeOH from the initial [3 + 2]-cycloadduct of 1d and nitrile imine 7d generat...
Scheme 5: Formation of the thermally stable, initially formed [3 + 2]-cycloadduct 10c obtained from 1e and ni...
Figure 3: Electronic absorption spectra for selected a) naphthoquinone-derived (9c, 9d, 9g) and b) anthraquin...
Beilstein J. Org. Chem. 2021, 17, 1096–1140, doi:10.3762/bjoc.17.86
Graphical Abstract
Scheme 1: General strategy for the enantioselective synthesis of N-containing heterocycles from N-tert-butane...
Scheme 2: Methodologies for condensation of aldehydes and ketones with tert-butanesulfinamides (1).
Scheme 3: Transition models for cis-aziridines and trans-aziridines.
Scheme 4: Mechanism for the reduction of N-tert-butanesulfinyl imines.
Scheme 5: Transition models for the addition of organomagnesium and organolithium compounds to N-tert-butanes...
Scheme 6: Synthesis of 2,2-dibromoaziridines 15 from aldimines 14 and bromoform, and proposed non-chelation-c...
Scheme 7: Diastereoselective synthesis of aziridines from tert-butanesulfinyl imines.
Scheme 8: Synthesis of vinylaziridines 22 from aldimines 14 and 1,3-dibromopropene 23, and proposed chelation...
Scheme 9: Synthesis of vinylaziridines 27 from aldimines 14 and α-bromoesters 26, and proposed transition sta...
Scheme 10: Synthesis of 2-chloroaziridines 28 from aldimines 14 and dichloromethane, and proposed transition s...
Scheme 11: Synthesis of cis-vinylaziridines 30 and 31 from aldimines 14 and bromomethylbutenolide 29.
Scheme 12: Synthesis of 2-chloro-2-aroylaziridines 36 and 32 from aldimines 14, arylnitriles 34, and silyldich...
Scheme 13: Synthesis of trifluoromethylaziridines 39 and proposed transition state of the aziridination.
Scheme 14: Synthesis of aziridines 42 and proposed state transition.
Scheme 15: Synthesis of 1-substituted 2-azaspiro[3.3]heptanes, 1-phenyl-2-azaspiro[3.4]octane and 1-phenyl-2-a...
Scheme 16: Synthesis of 1-substituted 2,6-diazaspiro[3.3]heptanes 48 from chiral imines 14 and 1-Boc-azetidine...
Scheme 17: Synthesis of β-lactams 52 from chiral imines 14 and dimethyl malonate (49).
Scheme 18: Synthesis of spiro-β-lactam 57 from chiral (RS)-N-tert-butanesulfinyl isatin ketimine 53 and ethyl ...
Scheme 19: Synthesis of β-lactam 60, a precursor of (−)-batzelladine D (61) and (−)-13-epi-batzelladine D (62)...
Scheme 20: Rhodium-catalyzed asymmetric synthesis of 3-substituted pyrrolidines 66 from chiral imine (RS)-63 a...
Scheme 21: Asymmetric synthesis of 1,3-disubstituted isoindolines 69 and 70 from chiral imine 67.
Scheme 22: Asymmetric synthesis of cis-2,5-disubstituted pyrrolidines 73 from chiral imine (RS)-71.
Scheme 23: Asymmetric synthesis of 3-hydroxy-5-substituted pyrrolidin-2-ones 77 from chiral imine (RS)-74.
Scheme 24: Asymmetric synthesis of 4-hydroxy-5-substituted pyrrolidin-2-ones 80 from chiral imines 79.
Scheme 25: Asymmetric synthesis of 3-pyrrolines 82 from chiral imines 14 and ethyl 4-bromocrotonate (81).
Scheme 26: Asymmetric synthesis of γ-amino esters 84, and tetramic acid derivative 86 from chiral imines (RS)-...
Scheme 27: Asymmetric synthesis of α-methylene-γ-butyrolactams 90 from chiral imines (Z,SS)-87 and ethyl 2-bro...
Scheme 28: Asymmetric synthesis of methylenepyrrolidines 92 from chiral imines (RS)-14 and 2-(trimethysilylmet...
Scheme 29: Synthesis of dibenzoazaspirodecanes from cyclic N-tert-butanesulfinyl imines.
Scheme 30: Stereoselective synthesis of cyclopenta[c]proline derivatives 103 from β,γ-unsaturated α-amino acid...
Scheme 31: Stereoselective synthesis of alkaloids (−)-angustureine (107) and (−)-cuspareine (108).
Scheme 32: Stereoselective synthesis of alkaloids (−)-pelletierine (112) and (+)-coniine (117).
Scheme 33: Synthesis of piperidine alkaloids (+)-dihydropinidine (122a), (+)-isosolenopsin (122b) and (+)-isos...
Scheme 34: Stereoselective synthesis of the alkaloids(+)-sedamine (125) from chiral imine (SS)-119.
Scheme 35: Stereoselective synthesis of trans-5-hydroxy-6-substituted-2-piperidinones 127 and 129 from chiral ...
Scheme 36: Stereoselective synthesis of trans-5-hydroxy-6-substituted ethanone-2-piperidinones 132 from chiral...
Scheme 37: Stereoselective synthesis of trans-3-benzyl-5-hydroxy-6-substituted-2-piperidinones 136 from chiral...
Scheme 38: Stereoselective synthesis of trans-5-hydroxy-6-substituted 2-piperidinones 139 from chiral imine 138...
Scheme 39: Stereoselective synthesis of ʟ-hydroxypipecolic acid 145 from chiral imine 144.
Scheme 40: Synthesis of 1-substituted isoquinolones 147, 149 and 151.
Scheme 41: Stereoselective synthesis of 3-substituted dihydrobenzo[de]isoquinolinones 154.
Scheme 42: Enantioselective synthesis of alkaloids (S)-1-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (...
Scheme 43: Enantioselective synthesis of alkaloids (−)-cermizine B (171) and (+)-serratezomine E (172) develop...
Scheme 44: Stereoselective synthesis of (+)-isosolepnosin (177) and (+)-solepnosin (178) from homoallylamine d...
Scheme 45: Stereoselective synthesis of tetrahydroquinoline derivatives 184, 185 and 187 from chiral imines (RS...
Scheme 46: Stereoselective synthesis of pyridobenzofuran and pyridoindole derivatives 193 from homopropargylam...
Scheme 47: Stereoselective synthesis of 2-substituted 1,2,5,6-tetrahydropyridines 196 from chiral imines (RS)-...
Scheme 48: Stereoselective synthesis of 2-substituted trans-2,6-disubstituted piperidine 199 from chiral imine...
Scheme 49: Stereoselective synthesis of cis-2,6-disubstituted piperidines 200, and alkaloid (+)-241D, from chi...
Scheme 50: Stereoselective synthesis of 6-substituted piperidines-2,5-diones 206 and 1,7-diazaspiro[4.5]decane...
Scheme 51: Stereoselective synthesis of spirocyclic oxindoles 210 from chiral imines (RS)-53.
Scheme 52: Stereoselective synthesis of azaspiro compound 213 from chiral imine 211.
Scheme 53: Stereoselective synthesis of tetrahydroisoquinoline derivatives from chiral imines (RS)-214.
Scheme 54: Stereoselective synthesis of (−)-crispine A 223 from chiral imine (RS)-214.
Scheme 55: Synthesis of (−)-harmicine (228) using tert-butanesulfinamide through haloamide cyclization.
Scheme 56: Stereoselective synthesis of tetraponerines T1–T8.
Scheme 57: Stereoselective synthesis of phenanthroindolizidines 246a and (−)-tylophorine (246b), and phenanthr...
Scheme 58: Stereoselective synthesis of indoline, tetrahydroquinoline and tetrahydrobenzazepine derivatives 253...
Scheme 59: Stereoselective synthesis of (+)-epohelmin A (258) and (+)-epohelmin B (260) from aldimine (RS)-79.
Scheme 60: Stereoselective synthesis of (−)-epiquinamide (266) from chiral aldimine (SS)-261.
Scheme 61: Synthesis synthesis of (–)-hippodamine (273) and (+)-epi-hippodamine (272) using chiral sulfinyl am...
Scheme 62: Stereoselective synthesis of (+)-grandisine D (279) and (+)-amabiline (283).
Scheme 63: Stereoselective synthesis of (−)-epiquinamide (266) and (+)-swaisonine (291) from aldimine (SS)-126....
Scheme 64: Stereoselective synthesis of (+)-C(9a)-epi-epiquinamide (294).
Scheme 65: Stereoselective synthesis of (+)-lasubine II (298) from chiral aldimine (SS)-109.
Scheme 66: Stereoselective synthesis of (−)-epimyrtine (300a) and (−)-lasubine II (ent-302) from β-amino keton...
Scheme 67: Stereoselective synthesis of (−)-tabersonine (310), (−)-vincadifformine (311), and (−)-aspidospermi...
Scheme 68: Stereoselective synthesis of (+)-epohelmin A (258) and (+)-epohelmin B (260) from aldehyde 313 and ...
Scheme 69: Total synthesis of (+)-lysergic acid (323) from N-tert-butanesulfinamide (RS)-1.
Beilstein J. Org. Chem. 2021, 17, 819–865, doi:10.3762/bjoc.17.71
Graphical Abstract
Figure 1: Marketed drugs with acridine moiety.
Scheme 1: Synthesis of 4-arylacridinediones.
Scheme 2: Proposed mechanism for acridinedione synthesis.
Scheme 3: Synthesis of tetrahydrodibenzoacridinones.
Scheme 4: Synthesis of naphthoacridines.
Scheme 5: Plausible mechanism for naphthoacridines.
Figure 2: Benzoazepines based potent molecules.
Scheme 6: Synthesis of azepinone.
Scheme 7: Proposed mechanism for azepinone formation.
Scheme 8: Synthesis of benzoazulenen-1-one derivatives.
Scheme 9: Proposed mechanism for benzoazulene-1-one synthesis.
Figure 3: Indole-containing pharmacologically active molecules.
Scheme 10: Synthesis of functionalized indoles.
Scheme 11: Plausible mechanism for the synthesis of functionalized indoles.
Scheme 12: Synthesis of spirooxindoles.
Scheme 13: Synthesis of substituted spirooxindoles.
Scheme 14: Plausible mechanism for the synthesis of substituted spirooxindoles.
Scheme 15: Synthesis of pyrrolidinyl spirooxindoles.
Scheme 16: Proposed mechanism for pyrrolidinyl spirooxindoles.
Figure 4: Pyran-containing biologically active molecules.
Scheme 17: Synthesis of functionalized benzopyrans.
Scheme 18: Plausible mechanism for synthesis of benzopyran.
Scheme 19: Synthesis of indoline-spiro-fused pyran derivatives.
Scheme 20: Proposed mechanism for indoline-spiro-fused pyran.
Scheme 21: Synthesis of substituted naphthopyrans.
Figure 5: Marketed drugs with pyrrole ring.
Scheme 22: Synthesis of tetra-substituted pyrroles.
Scheme 23: Mechanism for silica-supported PPA-SiO2-catalyzed pyrrole synthesis.
Scheme 24: Synthesis of pyrrolo[1,10]-phenanthrolines.
Scheme 25: Proposed mechanism for pyrrolo[1,10]-phenanthrolines.
Figure 6: Marketed drugs and molecules containing pyrimidine and pyrimidinones skeletons.
Scheme 26: MWA-MCR pyrimidinone synthesis.
Scheme 27: Two proposed mechanisms for pyrimidinone synthesis.
Scheme 28: MWA multicomponent synthesis of dihydropyrimidinones.
Scheme 29: Proposed mechanism for dihydropyrimidinones.
Figure 7: Biologically active fused pyrimidines.
Scheme 30: MWA- MCR for the synthesis of pyrrolo[2,3-d]pyrimidines.
Scheme 31: Proposed mechanism for pyrrolo[2,3-d]pyrimidines.
Scheme 32: Synthesis of substituted pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 33: Probable pathway for pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 34: Synthesis of pyridopyrimidines.
Scheme 35: Plausible mechanism for the synthesis of pyridopyrimidines.
Scheme 36: Synthesis of dihydropyridopyrimidine and dihydropyrazolopyridine.
Scheme 37: Proposed mechanism for the formation of dihydropyridopyrimidine.
Scheme 38: Synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 39: Plausible mechanism for the synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 40: Synthesis of decorated imidazopyrimidines.
Scheme 41: Proposed mechanism for imidazopyrimidine synthesis.
Figure 8: Pharmacologically active molecules containing purine bases.
Scheme 42: Synthesis of aza-adenines.
Scheme 43: Synthesis of 5-aza-7-deazapurines.
Scheme 44: Proposed mechanism for deazapurines synthesis.
Figure 9: Biologically active molecules containing pyridine moiety.
Scheme 45: Synthesis of steroidal pyridines.
Scheme 46: Proposed mechanism for steroidal pyridine.
Scheme 47: Synthesis of N-alkylated 2-pyridones.
Scheme 48: Two possible mechanisms for pyridone synthesis.
Scheme 49: Synthesis of pyridone derivatives.
Scheme 50: Postulated mechanism for synthesis of pyridone.
Figure 10: Biologically active fused pyridines.
Scheme 51: Benzimidazole-imidazo[1,2-a]pyridines synthesis.
Scheme 52: Mechanism for the synthesis of benzimidazole-imidazo[1,2-a]pyridines.
Scheme 53: Synthesis of pyrazolo[3,4-b]pyridine-5-spirocycloalkanedione derivatives.
Scheme 54: Proposed mechanism for spiro-pyridines.
Scheme 55: Functionalized macrocyclane-fused pyrazolo[3,4-b]pyridine derivatives.
Scheme 56: Mechanism postulated for macrocyclane-fused pyrazolo[3,4-b]pyridine.
Scheme 57: Generation of pyrazolo[3,4-b]pyridines.
Scheme 58: Proposed mechanism for the synthesis of pyrazolo[3,4-b]pyridines.
Scheme 59: Proposed mechanism for the synthesis of azepinoindole.
Figure 11: Pharmaceutically important molecules with quinoline moiety.
Scheme 60: Povarov-mediated quinoline synthesis.
Scheme 61: Proposed mechanism for Povarov reaction.
Scheme 62: Synthesis of pyrazoloquinoline.
Scheme 63: Plausible mechanism for pyrazoloquinoline synthesis.
Figure 12: Quinazolinones as pharmacologically significant scaffolds.
Scheme 64: Four-component reaction for dihydroquinazolinone.
Scheme 65: Proposed mechanism for dihydroquinazolinones.
Scheme 66: Synthesis purine quinazolinone and PI3K-δ inhibitor.
Scheme 67: Synthesis of fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 68: Proposed mechanism for fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 69: On-water reaction for synthesis of thiazoloquinazolinone.
Scheme 70: Proposed mechanism for the thiazoloquinazolinone synthesis.
Scheme 71: β-Cyclodextrin-mediated synthesis of indoloquinazolinediones.
Scheme 72: Proposed mechanism for synthesis of indoloquinazolinediones.
Figure 13: Triazoles-containing marketted drugs and pharmacologically active molecules.
Scheme 73: Cu(I) DAPTA-catalyzed 1,2,3-triazole formation.
Scheme 74: Mechanism for Cu(I) DAPTA-catalyzed triazole formation.
Scheme 75: Synthesis of β-hydroxy-1,2,3-triazole.
Scheme 76: Proposed mechanism for synthesis of β-hydroxy-1,2,3-triazoles.
Scheme 77: Synthesis of bis-1,2,4-triazoles.
Scheme 78: Proposed mechanism for bis-1,2,4-triazoles synthesis.
Figure 14: Thiazole containing drugs.
Scheme 79: Synthesis of a substituted thiazole ring.
Scheme 80: Synthesis of pyrazolothiazoles.
Figure 15: Chromene containing drugs.
Scheme 81: Magnetic nanocatalyst-mediated aminochromene synthesis.
Scheme 82: Proposed mechanism for the synthesis of chromenes.
Beilstein J. Org. Chem. 2021, 17, 805–812, doi:10.3762/bjoc.17.69
Graphical Abstract
Figure 1: Generation of the six-membered byproduct A from thionation reactions using Lawesson’s reagent.
Figure 2: Work-up procedure for the reaction with LR.
Figure 3: Modified process for the synthesis of 2e via phase separation.
Scheme 1: Modified process for the synthesis of pincer ligand 4.
Scheme 2: Modified process for the synthesis of pincer-type ligand 6.
Beilstein J. Org. Chem. 2021, 17, 771–799, doi:10.3762/bjoc.17.67
Graphical Abstract
Scheme 1: The electron transfer process in EDA complexes.
Scheme 2: Synthesis of benzo[b]phosphorus oxide 3 initiated by an EDA complex.
Scheme 3: Mechanism of the synthesis of quinoxaline derivative 7.
Scheme 4: Synthesis of imidazole derivative 10 initiated by an EDA complex.
Scheme 5: Synthesis of sulfamoylation product 12 initiated by an EDA complex.
Scheme 6: Mechanism of the synthesis of sulfamoylation product 12.
Scheme 7: Synthesis of indole derivative 22 initiated by an EDA complex.
Scheme 8: Synthesis of perfluoroalkylated pyrimidines 26 initiated by an EDA complex.
Scheme 9: Synthesis of phenanthridine derivative 29 initiated by an EDA complex.
Scheme 10: Synthesis of cis-tetrahydroquinoline derivative 32 initiated by an EDA complex.
Scheme 11: Mechanism of the synthesis of cis-tetrahydroquinoline derivative 32.
Scheme 12: Synthesis of phenanthridine derivative 38 initiated by an EDA complex.
Scheme 13: Synthesis of spiropyrroline derivative 40 initiated by an EDA complex.
Scheme 14: Synthesis of benzothiazole derivative 43 initiated by an EDA complex.
Scheme 15: Synthesis of perfluoroalkyl-s-triazine derivative 45 initiated by an EDA complex.
Scheme 16: Synthesis of indoline derivative 47 initiated by an EDA complex.
Scheme 17: Mechanism of the synthesis of spirocyclic indoline derivative 47.
Scheme 18: Synthesis of cyclobutane product 50 initiated by an EDA complex.
Scheme 19: Mechanism of the synthesis of spirocyclic indoline derivative 50.
Scheme 20: Synthesis of 1,3-oxazolidine compound 59 initiated by an EDA complex.
Scheme 21: Synthesis of trifluoromethylated product 61 initiated by an EDA complex.
Scheme 22: Synthesis of indole alkylation product 64 initiated by an EDA complex.
Scheme 23: Synthesis of perfluoroalkylation product 67 initiated by an EDA complex.
Scheme 24: Synthesis of hydrotrifluoromethylated product 70 initiated by an EDA complex.
Scheme 25: Synthesis of β-trifluoromethylated alkyne product 71 initiated by an EDA complex.
Scheme 26: Mechanism of the synthesis of 2-phenylthiophene derivative 74.
Scheme 27: Synthesis of allylated product 80 initiated by an EDA complex.
Scheme 28: Synthesis of trifluoromethyl-substituted alkynyl product 84 initiated by an EDA complex.
Scheme 29: Synthesis of dearomatized fluoroalkylation product 86 initiated by an EDA complex.
Scheme 30: Mechanism of the synthesis of dearomatized fluoroalkylation product 86.
Scheme 31: Synthesis of C(sp3)–H allylation product 91 initiated by an EDA complex.
Scheme 32: Synthesis of perfluoroalkylation product 93 initiated by an EDA complex.
Scheme 33: Synthesis of spirocyclic indolene derivative 95 initiated by an EDA complex.
Scheme 34: Synthesis of perfluoroalkylation product 97 initiated by an EDA complex.
Scheme 35: Synthesis of alkylated indole derivative 100 initiated by an EDA complex.
Scheme 36: Mechanism of the synthesis of alkylated indole derivative 100.
Scheme 37: Synthesis of arylated oxidized indole derivative 108 initiated by an EDA complex.
Scheme 38: Synthesis of 4-ketoaldehyde derivative 111 initiated by an EDA complex.
Scheme 39: Mechanism of the synthesis of 4-ketoaldehyde derivative 111.
Scheme 40: Synthesis of perfluoroalkylated olefin 118 initiated by an EDA complex.
Scheme 41: Synthesis of alkylation product 121 initiated by an EDA complex.
Scheme 42: Synthesis of acylation product 123 initiated by an EDA complex.
Scheme 43: Mechanism of the synthesis of acylation product 123.
Scheme 44: Synthesis of trifluoromethylation product 126 initiated by an EDA complex.
Scheme 45: Synthesis of unnatural α-amino acid 129 initiated by an EDA complex.
Scheme 46: Synthesis of thioether derivative 132 initiated by an EDA complex.
Scheme 47: Synthesis of S-aryl dithiocarbamate product 135 initiated by an EDA complex.
Scheme 48: Mechanism of the synthesis of S-aryl dithiocarbamate product 135.
Scheme 49: Synthesis of thioether product 141 initiated by an EDA complex.
Scheme 50: Mechanism of the synthesis of borate product 144.
Scheme 51: Synthesis of boronation product 148 initiated by an EDA complex.
Scheme 52: Synthesis of boration product 151 initiated by an EDA complex.
Scheme 53: Synthesis of boronic acid ester derivative 154 initiated by an EDA complex.
Scheme 54: Synthesis of β-azide product 157 initiated by an EDA complex.
Scheme 55: Decarboxylation reaction initiated by an EDA complex.
Scheme 56: Synthesis of amidated product 162 initiated by an EDA complex.
Scheme 57: Synthesis of diethyl phenylphosphonate 165 initiated by an EDA complex.
Scheme 58: Mechanism of the synthesis of diethyl phenylphosphonate derivative 165.
Scheme 59: Synthesis of (Z)-2-iodovinyl phenyl ether 168 initiated by an EDA complex.
Scheme 60: Mechanism of the synthesis of (Z)-2-iodovinyl phenyl ether derivative 168.
Scheme 61: Dehalogenation reaction initiated by an EDA complex.
Beilstein J. Org. Chem. 2021, 17, 273–282, doi:10.3762/bjoc.17.26
Graphical Abstract
Scheme 1: Synthetic pathways for the preparation of o-quinone derivatives with annulated 1,3-dithiole ring.
Figure 1: Active methylene compounds used for the preparation of gem-dithiolates.
Figure 2: Fragment of coordination polymer chain of adduct 8 in the crystal phase. Hydrogen atoms and CF3 gro...
Scheme 2: The tentative pathway for the formation of o-quinone 7 with annulated thiete ring.
Scheme 3: Reactions of o-quinone 6a.
Scheme 4: Stepwise reduction of o-quinones with metals to semiquinonates and catecholates, respectively.
Beilstein J. Org. Chem. 2020, 16, 2739–2748, doi:10.3762/bjoc.16.224
Graphical Abstract
Scheme 1: Reaction of purine (2) with tetrakis(trifluoromethyl)-1,3-dithietane (1).
Figure 1: Crystal structure of 2a, with the thermal ellipsoids drawn at 30% probability.
Scheme 2: Reaction of 4-azabenzimidazole (3) with tetrakis(trifluoromethyl)-1,3-dithietane (1).
Scheme 3: Reaction of 5-azabenzimidazole (4) with 1.
Scheme 4: Reaction of adenine (5) and 2-fluoroadenine (6) with tetrakis(trifluoromethyl)-1,3-dithietane (1).
Scheme 5: Reaction of theophylline (7) with tetrakis(trifluoromethyl)-1,3-dithietane (1).
Figure 2: Crystal structure of 7a, with the thermal ellipsoids drawn at 30% probability.
Scheme 6: Probable mechanism of the reaction of tetrakis(trifluoromethyl)-1,3-dithietane (1) with compounds 2–...
Figure 3: Top: 19F NMR spectra of 3a acquired over a sample temperature range of 223–373 K. Left: Fitted plot...
Figure 4: DFT-optimized structures of the two rotamers of 3a. Left: Lower-energy rotamer. Right: Higher-energ...
Beilstein J. Org. Chem. 2020, 16, 2212–2259, doi:10.3762/bjoc.16.186
Graphical Abstract
Figure 1: Representation of corannulene (1) and sumanene (2), the subunits of fullerene (C60).
Scheme 1: Mehta’s unsuccessful effort for the synthesis of sumanene scaffold 2.
Scheme 2: First synthesis of sumanene 2 by Sakurai et al. from norbornadiene 10.
Scheme 3: Synthesis of trimethylsumanene 28 from easily accessible norbornadiene (10).
Scheme 4: Generation of anions 29–31 and the preparation of tris(trimethylsilyl)sumanene 32.
Scheme 5: Synthesis of tri- and hexa-substituted sumanene derivatives.
Scheme 6: Synthesis of bowl-shaped π-extended sumanene derivatives 37a–f.
Scheme 7: Synthesis of monooxasumanene 38, trioxosumanene 40 along with imination of them.
Scheme 8: Synthesis of trimethylsumanenetrione 46 and exo-functionalized products 45a,b.
Scheme 9: Synthesis of bisumanenylidene 47 and sumanene dimer 48 from 2.
Scheme 10: The mono-substitution of 2 to generate diverse mono-sumanene derivatives 49a–d.
Scheme 11: Synthesis of sumanene building block 53 useful for further extension.
Scheme 12: Synthesis of hexafluorosumanene derivative 55 by Sakurai and co-workers.
Scheme 13: Preparation of sumanene-based carbene 60 and its reaction with cyclohexane.
Scheme 14: Barton–Kellogg reaction for the synthesis of sterically hindered alkenes.
Scheme 15: Synthesis of hydroxysumanene 68 by employing Baeyer–Villiger oxidation.
Scheme 16: Synthesis of sumanene derivatives having functionality at an internal carbon.
Scheme 17: Mechanism for nucleophilic substitution reaction at the internal carbon.
Scheme 18: Synthesis of diverse monosubstituted sumanene derivatives.
Scheme 19: Synthesis of di- and trisubstituted sumanene derivatives from sumanene (2).
Scheme 20: Preparation of monochlorosumanene 88 and hydrogenation of sumanene (2).
Scheme 21: The dimer 90 and bissumanenyl 92 achieved from halosumannes.
Scheme 22: Pyrenylsumanene 93 involving the Suzuki-coupling as a key transformation.
Scheme 23: Synthesis of various hexaarylsumanene derivatives using the Suzuki-coupling reaction.
Scheme 24: Synthesis of hexasubstituted sumanene derivatives 96 and 97.
Scheme 25: Synthesis of thioalkylsumanenes via an aromatic nucleophilic substitution reaction.
Scheme 26: Synthesis of tris(ethoxycarbonylethenyl)sumanene derivative 108.
Scheme 27: Synthesis of ferrocenyl-based sumanene derivatives.
Scheme 28: Synthesis of sumanenylferrocene architectures 118 and 119 via Negishi coupling.
Scheme 29: Diosmylation and the synthesis of phenylboronate ester 121 of sumanene.
Scheme 30: Synthesis of the iron-complex of sumanene.
Scheme 31: Synthesis of tri- and mononuclear sumanenyl zirconocene complexes.
Scheme 32: Synthesis of [CpRu(η6-sumanene)]PF6.
Scheme 33: Preparation of sumanene-based porous coordination networks 127 (spherical tetramer units) and 128 (...
Scheme 34: Synthesis of sumanenylhafnocene complexes 129 and 130.
Scheme 35: Synthesis of 134 and 135 along with PdII coordination complex 136.
Scheme 36: Synthesis of alkali metals sumanene complex K7(C21H102−)2(C21H93−)·8THF (137) containing di- and tr...
Scheme 37: The encapsulation of a Cs+ ion between two sumanenyl anions.
Scheme 38: Synthesis of monothiasumanene 140 and dithiasumanene 141 from 139.
Scheme 39: Synthesis of trithiasumanene 151 by Otsubo and his co-workers.
Scheme 40: Synthesis of trithiasumanene derivatives 155 and 156.
Scheme 41: Synthetic route towards hexathiolated trithiasumanenes 158.
Scheme 42: Synthesis of triselenasumanene 160 by Shao and teammates.
Scheme 43: Synthesis of tritellurasumanene derivatives from triphenylene skeletons.
Scheme 44: Synthesis of pyrazine-fused sumanene architectures through condensation reaction.
Scheme 45: Treatment of the trichalcogenasumanenes with diverse oxidative reagents.
Scheme 46: Ring-opening reaction with H2O2 and oxone of heterasumanenes 178 and 179.
Scheme 47: Synthesis of polycyclic compounds from sumanene derivatives.
Scheme 48: Synthesis of diimide-based heterocycles reported by Shao’s and co-workers.
Scheme 49: Synthesis of pristine trichalcogenasumanenes, 151, 205, and 206.
Scheme 50: Synthesis of trichalcogenasumanenes via hexaiodotriphenylene precursor 208.
Scheme 51: Synthesis of trisilasumanenes 214 and 215.
Scheme 52: Synthesis of trisilasumanene derivatives 218 and 219.
Scheme 53: Synthesis of novel trigermasumanene derivative 223.
Scheme 54: An attempt towards the synthesis of tristannasumanene derivative 228.
Scheme 55: Synthesis of triphosphasumanene trisulfide 232 from commercially available 229.
Scheme 56: The doping of sumanene derivatives with chalcogens (S, Se, Te) and phosphorus.
Scheme 57: Synthesis of heterasumanene containing three different heteroatoms.
Scheme 58: Synthesis of trichalcogenasumanene derivatives 240 and 179.
Scheme 59: Preparation of trichalcogenasumanenes 245 and 248.
Scheme 60: Design and synthesis of trichalcogenasumanene derivatives 252 and 178.
Scheme 61: Synthesis of spirosumanenes 264–269 and non-spiroheterasumanenes 258–263.
Scheme 62: Synthesis of sumanene-type hetero polycyclic compounds.
Scheme 63: Synthesis of triazasumanenes 288 and its sulfone congener 287.
Scheme 64: Synthesis of C3-symmetric chiral triaryltriazasumanenes via cross-coupling reaction.
Scheme 65: Synthesis of mononaphthosumanene 293 using Suzuki coupling as a key step.
Scheme 66: Synthesis of di- and trinaphthosumanene derivatives 302–304.
Scheme 67: Synthesis of hemifullerene skeletons by Hirao’s group.
Scheme 68: Design and construction of C70 fragment from a C60 sumanene fragment.
Beilstein J. Org. Chem. 2020, 16, 1881–1900, doi:10.3762/bjoc.16.156
Graphical Abstract
Figure 1: The benzimidazoles I–IV, dihydropyrimidinones/-thiones V–VIII, and 2-amino-4-aryl-3,5-dicarbonitril...
Scheme 1: NDL-catalyzed synthesis of i) 1,2-disubstituted benzimidazoles 3, ii) dihydropyrimidinones/-thiones ...
Figure 2: XRD pattern of the NDL catalyst.
Figure 3: FTIR spectrum of the NDL catalyst.
Figure 4: Raman spectrum of the NDL catalyst.
Figure 5: SEM images of the NDL catalyst.
Figure 6: EDAX analysis of the NDL catalyst.
Scheme 2: Unexpected formation of the bisimine I, 3h, from o-phenylenediamine (1) and salicylaldehyde (2h).
Figure 7: 1H NMR spectrum of 2,2'-((1E,1'E)-(1,2-phenylenebis(azanylylidene))bis (methanylylidene))diphenol (...
Figure 8: XRD pattern of a) the fresh NDL catalyst; b) the recovered NDL catalyst after the 7th cycle of the ...
Beilstein J. Org. Chem. 2020, 16, 1100–1110, doi:10.3762/bjoc.16.97
Graphical Abstract
Figure 1: Structures of pseudosporamide (1) and pseudosporamicins A–C (2–4).
Figure 2: COSY, key HMBC and ROESY correlations of pseudosporamide (1).
Figure 3: 1H NMR ΔδS−R values for PGME amides 5a and 5b obtained from compound 1.
Figure 4: The opposite axial chirality around the biaryl C-6–C-7'' bond influenced by the C-2 configuration i...
Figure 5: The experimental and calculated ECD spectra in MeCN.
Figure 6: COSY, key HMBC and NOESY correlations of compound 2.
Figure 7: NOESY correlations for the spiroacetal moiety of compound 2.
Figure 8: Selected examples of oligomycin-class metabolites from actinomycetes.
Beilstein J. Org. Chem. 2020, 16, 791–797, doi:10.3762/bjoc.16.72
Graphical Abstract
Scheme 1: Chemical structures of dicyclopenta-fused pyrene derivatives i–iii, peropyrene and the dicyclopenta...
Scheme 2: Synthetic route towards compound 1. a) B2pin2, dtbpy, [Ir(OMe)cod]2, cyclohexane, 70 °C, 20 h, 67%;...
Figure 1: High-resolution MALDI-TOF mass spectrum of 1. Inset: isotopic distribution compared to mass spectru...
Figure 2: Single-crystal X-ray structure of 1. (a) Top view and (b) side view of the (P,P) isomer. c) Crystal...
Figure 3: (a) UV–vis absorption spectra of precursor 5 and 1 in CH2Cl2 solution (10−5 M). Inset: photograph o...
Figure 4: Molecular orbitals of peropyrene derivative 6 and the dicyclopenta-fused peropyrene 1.
Beilstein J. Org. Chem. 2020, 16, 515–523, doi:10.3762/bjoc.16.47
Graphical Abstract
Scheme 1: Possible formation of reaction products starting from 1 via seleniranium 2 or thiiranium cations 3.
Scheme 2: Unusual regio- and stereoselective nucleophilic reactions of thiaselenole 1 at two centers of the s...
Scheme 3: Reactions of thiaselenole 1 with С- and S-centered nucleophiles affording new families of linear un...
Scheme 4: The reactions of thiaselenole 1 with the formation of polyfunctionalized 2,3-dihydro-1,4-thiaseleni...
Scheme 5: The synthesis of new 1,3-thiaselenole ensembles by reactions of thiaselenole 1 with mercapto benzaz...
Scheme 6: The formation of product 4 via compound 5 by the reaction of thiaselenole 1 with potassium selenocy...
Figure 1: Monitoring the reaction of thiaselenole 1 with KSeCN by 1H NMR spectroscopy (in accordance with the...
Scheme 7: The reaction pathway for the formation of compounds 4 and 5.
Scheme 8: Synthesis of new ensembles of 1,3-thiaselenol-2-ylmethyl selenides 6a–l (77Se NMR data are included...
Scheme 9: The synthesis of vinyl selenides 7a,b through nucleophilic addition of 1,3-thiaselenol-2-ylmethylse...
Scheme 10: One-pot synthesis of diselenide 8 from thiaselenole 1 (77Se NMR data are included).
Scheme 11: Synthesis of compounds 6a–j from diselenide 8.
Beilstein J. Org. Chem. 2020, 16, 200–211, doi:10.3762/bjoc.16.23
Graphical Abstract
Figure 1: Chemical structure of representative approved drugs containing a spirocyclic moiety.
Scheme 1: Synthetic strategies for accessing pyrrolocyclopentenone derivatives, including the novel couple/pa...
Scheme 2: Couple/pair approach using combined KA2 and Pauson–Khand multicomponent reactions.
Scheme 3: Follow-up chemistry on compound 5 taking advantage of the enone chemistry. Reaction conditions. (i)...
Figure 2: Top: Selected NOE contacts from NOESY 1D spectra of compound 36; bottom: low energy conformer of 36...
Figure 3: PCA plot resulting from the correlation between PC1 vs PC2, showing the positioning in the chemical...
Figure 4: PMI plot showing the skeletal diversity of compounds 3–39 (blue diamonds) with respect to the refer...
Beilstein J. Org. Chem. 2020, 16, 15–21, doi:10.3762/bjoc.16.3
Graphical Abstract
Figure 1: Substrates used for the Mizoroki–Heck reaction in this study.
Figure 2: Structures of the identified side products 4 and 5.
Scheme 1: Scope of the method for analogs derived from 1 and 2. The ratio of isomers is given (E/Z or β/α) in...
Scheme 2: Dealkylation of fluorinated analog 23 under the Mizoroki–Heck reaction conditions.